David Kandzari (Atlanta, USA) tells Cardiovascular News at CRT 2019 that renal denervation is typically showing magnitudes of blood pressure reduction that are clinically meaningful (approximately 10mmHg reduction in systolic and 5mmHg diastolic). While, these values are theoretically achievable with “a single antihypertensive pharmaceutical agent”, surveys will seek to ascertain whether patients prefer a one-off minimally invasive procedure, or a life-long commitment to medication—in a scenario where non-adherence to medication is seen in upwards of 40% of the population.
